MedTrace Logo

A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

NCT05165849 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2022-05-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety/tolerability, pharmacokinetics, and efficacy of GFS101A in combination with Toripalimab in patients with advanced solid tumors.

Conditions

Interventions

DRUG

GFS101A

GFS101A will be administrated intravenously Q3W.

DRUG

Toripalimab

Toripalimab with fixed dose of 240 mg Q3W administered intravenously.

Sponsors & Collaborators

  • Zhejiang Genfleet Therapeutics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2022-05-11
Completion
2022-05-11

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05165849 on ClinicalTrials.gov